🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
13/10/2022 1,4100 USD
14/07/2022 1,4100 USD
13/04/2022 1,4100 USD
13/01/2022 1,4100 USD
14/10/2021 1,3000 USD
14/07/2021 1,3000 USD
14/04/2021 1,3000 USD
14/01/2021 1,3000 USD
14/10/2020 1,1800 USD
14/07/2020 1,1800 USD
14/04/2020 1,1800 USD
14/01/2020 1,1800 USD
11/10/2019 1,0700 USD
12/07/2019 1,0700 USD
12/04/2019 1,0700 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
27/06/2017 72,70 73,06 72,25 72,39 -0,48% 1,11% 4.490.600
26/06/2017 72,79 72,94 72,41 72,74 +0,14% 0,73% 4.019.500
23/06/2017 73,20 73,49 72,26 72,64 -0,74% 1,68% 7.064.500
22/06/2017 71,49 73,67 71,41 73,18 +2,58% 3,16% 9.998.900
21/06/2017 71,11 71,70 71,05 71,34 +0,17% 0,91% 6.096.800
20/06/2017 71,44 71,81 71,16 71,22 -0,17% 0,91% 6.542.800
19/06/2017 71,11 71,59 70,94 71,34 +0,41% 0,91% 6.396.300
16/06/2017 70,80 71,12 70,49 71,05 +0,64% 0,89% 9.342.300
15/06/2017 70,34 70,65 69,88 70,60 +0,11% 1,09% 4.682.700
14/06/2017 69,48 70,79 69,37 70,52 +1,22% 2,04% 6.639.100
13/06/2017 69,62 70,03 69,42 69,67 +0,20% 0,88% 5.269.000
12/06/2017 69,79 69,90 69,25 69,53 -0,20% 0,93% 6.084.300
09/06/2017 68,80 69,83 68,72 69,67 +1,32% 1,61% 6.159.800
08/06/2017 68,75 69,05 68,33 68,76 +0,01% 1,05% 6.082.500
07/06/2017 68,01 69,32 68,01 68,75 +1,30% 1,93% 8.406.300
06/06/2017 67,48 68,10 67,37 67,87 +0,53% 1,08% 5.494.500
05/06/2017 67,25 67,86 66,88 67,51 +0,39% 1,46% 4.918.100
02/06/2017 66,81 67,31 66,62 67,25 +0,81% 1,03% 5.646.000
01/06/2017 66,26 66,72 66,12 66,71 +1,05% 0,91% 4.554.700
31/05/2017 66,24 66,41 65,61 66,02 +0,00% 1,21% 6.935.800
30/05/2017 65,89 66,20 65,81 66,02 -0,06% 0,59% 4.803.900
26/05/2017 66,14 66,41 65,85 66,06 -0,39% 0,85% 4.083.000
25/05/2017 66,06 66,57 65,80 66,32 +0,59% 1,17% 4.058.300
24/05/2017 65,79 66,12 65,57 65,93 +0,14% 0,84% 3.174.600
23/05/2017 65,44 66,26 65,43 65,84 +0,61% 1,27% 4.676.500
22/05/2017 65,55 65,62 64,80 65,44 -0,21% 1,25% 5.541.700
19/05/2017 65,74 66,01 65,31 65,58 -0,08% 1,06% 6.731.800
18/05/2017 65,37 66,10 65,20 65,63 +0,40% 1,38% 6.001.000
17/05/2017 66,85 66,85 64,61 65,37 -2,21% 3,35% 12.771.400
16/05/2017 66,73 66,92 66,33 66,85 +0,27% 0,88% 6.313.500